A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Condition(s) studied

Investigational drug(s) / intervention(s)

APG777: APG777 subcutaneous injection

APG777: APG777 subcutaneous injection every 12 weeks

APG777: APG777 subcutaneous injection every 24 weeks

Study summary

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).

The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

Eligibility

Primary outcome measure(s)

• Number of Participants with Treatment Emergent Adverse Events — Up to 3 years

Trial sites (73)

+ 33 more sites — see the full list on the official registry below.

More Apogee Therapeutics, Inc. trials in Spain

Other trials for the same condition